Literature DB >> 19067791

Combining mutations of charged residues at the A2 domain interface enhances factor VIII stability over single point mutations.

H Wakabayashi1, A E Griffiths, P J Fay.   

Abstract

BACKGROUND: Factor (F) VIII consists of a heavy chain (A1A2B domains) and light chain (A3C1C2 domains), while the contiguous A1A2 domains are separate subunits in the cofactor, FVIIIa. Recently we reported that procofactor stability at elevated temperature and cofactor stability over an extended time course were increased following replacement of individual charged residues (Asp(D)519, Glu(E)665 or Glu(E)1984) with either Ala (A) or Val (V) (Wakabayashi et al., Blood, 112, 2761, 2008).
OBJECTIVES: In the current study we generated combination mutants at these three sites to examine any additive and/or synergistic effects of these mutations on stability.
METHODS: Studies assessing FVIII stability involved monitoring decay rates of FVIII at 55 degrees C or in guanidinium, decay of FVIIIa following A2 subunit dissociation, and thrombin generation at low (0.3 nmol L(-1)) FVIII concentration. RESULTS AND
CONCLUSIONS: Similar tendencies were observed within each group of variants. Variants with mutations at D519 and either E665 or E1984 (Group A) generally showed significantly better stability as compared with single mutants. Most variants with mutations at E665 and at E1984 (Group B) did not show significant improvement. Triple mutants with mutations at D519, E665 and E1984 (Group C) showed improvement to a similar degree as the Group A double mutants. Overall, these results indicate that selected combinations of mutations to reduce charge and/or increase hydrophobicity at the A2/A1 and A2/A3 domain interfaces yield FVIII reagents with improved stability parameters.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19067791      PMCID: PMC3136035          DOI: 10.1111/j.1538-7836.2008.03256.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  26 in total

Review 1.  Activation of factor VIII and mechanisms of cofactor action.

Authors:  Philip J Fay
Journal:  Blood Rev       Date:  2004-03       Impact factor: 8.250

2.  Residues 110-126 in the A1 domain of factor VIII contain a Ca2+ binding site required for cofactor activity.

Authors:  Hironao Wakabayashi; Jan Freas; Qian Zhou; Philip J Fay
Journal:  J Biol Chem       Date:  2004-01-13       Impact factor: 5.157

3.  Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa.

Authors:  S W Pipe; E L Saenko; A N Eickhorst; G Kemball-Cook; R J Kaufman
Journal:  Blood       Date:  2001-02-01       Impact factor: 22.113

4.  Hemophilia A mutations within the factor VIII A2-A3 subunit interface destabilize factor VIIIa and cause one-stage/two-stage activity discrepancy.

Authors:  William H Hakeos; Hongzhi Miao; Nongnuch Sirachainan; Geoffrey Kemball-Cook; Evgueni L Saenko; Randal J Kaufman; Steven W Pipe
Journal:  Thromb Haemost       Date:  2002-11       Impact factor: 5.249

5.  Metal ion-independent association of factor VIII subunits and the roles of calcium and copper ions for cofactor activity and inter-subunit affinity.

Authors:  H Wakabayashi; M E Koszelak; M Mastri; P J Fay
Journal:  Biochemistry       Date:  2001-08-28       Impact factor: 3.162

6.  pH-dependent denaturation of thrombin-activated porcine factor VIII.

Authors:  P Lollar; C G Parker
Journal:  J Biol Chem       Date:  1990-01-25       Impact factor: 5.157

7.  Calibrated automated thrombin generation measurement in clotting plasma.

Authors:  H Coenraad Hemker; Peter Giesen; Raed Al Dieri; Véronique Regnault; Eric de Smedt; Rob Wagenvoord; Thomas Lecompte; Suzette Béguin
Journal:  Pathophysiol Haemost Thromb       Date:  2003

8.  Expression and characterization of recombinant murine factor VIII.

Authors:  Christopher Doering; Ernest T Parker; John F Healey; Heather N Craddock; Rachel T Barrow; Pete Lollar
Journal:  Thromb Haemost       Date:  2002-09       Impact factor: 5.249

9.  Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside.

Authors:  L T Mimms; G Zampighi; Y Nozaki; C Tanford; J A Reynolds
Journal:  Biochemistry       Date:  1981-02-17       Impact factor: 3.162

10.  Reconstitution of human factor VIII from isolated subunits.

Authors:  P J Fay
Journal:  Arch Biochem Biophys       Date:  1988-05-01       Impact factor: 4.013

View more
  19 in total

1.  Modification of interdomain interfaces within the A3C1C2 subunit of factor VIII affects its stability and activity.

Authors:  Hironao Wakabayashi; Philip J Fay
Journal:  Biochemistry       Date:  2013-05-21       Impact factor: 3.162

2.  Factor VIII lacking the C2 domain retains cofactor activity in vitro.

Authors:  Hironao Wakabayashi; Amy E Griffiths; Philip J Fay
Journal:  J Biol Chem       Date:  2010-06-07       Impact factor: 5.157

3.  Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.

Authors:  Krithika A Shetty; Matthew P Kosloski; Donald E Mager; Sathy V Balu-Iyer
Journal:  Biopharm Drug Dispos       Date:  2016-09-13       Impact factor: 1.627

4.  Mass spectrometry-assisted study reveals that lysine residues 1967 and 1968 have opposite contribution to stability of activated factor VIII.

Authors:  Esther Bloem; Henriet Meems; Maartje van den Biggelaar; Carmen van der Zwaan; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2012-01-03       Impact factor: 5.157

5.  Enhancing factor VIII and VIIIa stability by combining mutations at the A2 domain interface and A1-C2 domain interface.

Authors:  H Wakabayashi; A E Griffiths; P J Fay
Journal:  J Thromb Haemost       Date:  2012-03       Impact factor: 5.824

6.  Noncovalent stabilization of the factor VIII A2 domain enhances efficacy in hemophilia A mouse vascular injury models.

Authors:  Lilley Leong; Derek Sim; Chandra Patel; Katherine Tran; Perry Liu; Elena Ho; Thomas Thompson; Peter J Kretschmer; Hironao Wakabayashi; Philip J Fay; John E Murphy
Journal:  Blood       Date:  2014-10-20       Impact factor: 22.113

7.  Allometry of factor VIII and informed scaling of next-generation therapeutic proteins.

Authors:  Matthew P Kosloski; Dipak S Pisal; Donald E Mager; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2013-04-25       Impact factor: 3.534

8.  Increasing hydrophobicity or disulfide bridging at the factor VIII A1 and C2 domain interface enhances procofactor stability.

Authors:  Hironao Wakabayashi; Amy E Griffiths; Philip J Fay
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

9.  Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo.

Authors:  Matthew P Kosloski; Krithika A Shetty; Hironao Wakabayashi; Philip J Fay; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2014-06-17       Impact factor: 4.009

Review 10.  Computational design of affinity and specificity at protein-protein interfaces.

Authors:  John Karanicolas; Brian Kuhlman
Journal:  Curr Opin Struct Biol       Date:  2009-07-29       Impact factor: 6.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.